Get the Stockscreener App
0.8121
5.47%
0.0421
After Hours:
.82
0.0079
+0.97%
Scynexis Inc stock is traded at $0.8121, with a volume of 1.03M.
It is up +5.47% in the last 24 hours and down -27.49% over the past month.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$0.77
Open:
$0.7855
24h Volume:
1.03M
Relative Volume:
3.14
Market Cap:
$34.05M
Revenue:
$3.26M
Net Income/Loss:
$-19.52M
P/E Ratio:
-2.0303
EPS:
-0.4
Net Cash Flow:
$-24.10M
1W Performance:
+3.02%
1M Performance:
-27.49%
6M Performance:
-6.66%
1Y Performance:
-46.92%
1-Day Range:
$0.765
$0.8476
1-Week Range:
$0.732
$0.8476
52-Week Range:
$0.66
$1.62
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201-884-5485
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.8121 | 32.28M | 3.26M | -19.52M | -24.10M | -0.40 |
|
ZTS
Zoetis Inc
|
142.26 | 62.54B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 43.30B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.08 | 40.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.02 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.06 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-21 | Initiated | Guggenheim | Buy |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-18 | Upgrade | Needham | Hold → Buy |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-10-17 | Initiated | ROTH Capital | Buy |
| May-09-17 | Downgrade | Needham | Buy → Hold |
| Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-20-16 | Initiated | H.C. Wainwright | Buy |
| Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Aug-17-16 | Initiated | Guggenheim | Buy |
| Aug-09-16 | Reiterated | Needham | Buy |
| Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Mar-28-16 | Initiated | Brean Capital | Buy |
| Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
| Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-10-15 | Initiated | Needham | Buy |
| May-29-14 | Initiated | Canaccord Genuity | Buy |
| May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
What MACD signals say about SCYNEXIS Inc.Take Profit & Daily Profit Focused Stock Screening - newser.com
Does SCYNEXIS Inc. fit your quant trading model2025 Year in Review & Fast Entry and Exit Trade Plans - newser.com
How interest rate cuts could boost SCYNEXIS Inc. stock2025 Retail Activity & High Yield Stock Recommendations - newser.com
Building trade automation scripts for SCYNEXIS Inc.July 2025 Setups & Technical Confirmation Trade Alerts - newser.com
Regression analysis insights on SCYNEXIS Inc. performanceShort Setup & Capital Efficient Trade Techniques - newser.com
Will SCYNEXIS Inc. stock recover faster than peers2025 Institutional Moves & Weekly Breakout Watchlists - newser.com
SCYNEXIS Inc. stock daily chart insightsMarket Sentiment Summary & Consistent Growth Equity Picks - newser.com
Is SCYNEXIS Inc. stock ready for a breakout2025 Price Momentum & Weekly High Return Forecasts - newser.com
Trend analysis for SCYNEXIS Inc. this weekJuly 2025 Intraday Action & Growth Focused Entry Point Reports - newser.com
Has SCYNEXIS Inc. found a price floorJuly 2025 Update & High Accuracy Trade Alerts - newser.com
Technical signs of recovery in SCYNEXIS Inc.Stop Loss & Safe Entry Momentum Tips - newser.com
What momentum shifts mean for SCYNEXIS Inc.Bear Alert & Daily Entry Point Trade Alerts - newser.com
Why SCYNEXIS Inc. stock remains resilientWeekly Trade Analysis & Reliable Entry Point Alerts - newser.com
How SCYNEXIS Inc. stock reacts to Fed rate cuts2025 Top Gainers & Daily Oversold Bounce Ideas - newser.com
Can SCYNEXIS Inc. (135A) stock attract analyst upgradesJuly 2025 Earnings & Long Hold Capital Preservation Tips - newser.com
SCYNEXIS Inc. recovery potential after sell offJuly 2025 Levels & Community Trade Idea Sharing Platform - newser.com
Why SCYNEXIS Inc. (135A) stock could rally stronglyWeekly Stock Summary & Risk Adjusted Buy and Sell Alerts - newser.com
How strong is SCYNEXIS Inc. (135A) stock earnings growthWatch List & Daily Entry Point Trade Alerts - newser.com
What data driven models say about SCYNEXIS Inc.’s futureJuly 2025 Institutional & Stepwise Swing Trade Plans - newser.com
Multi asset correlation models including SCYNEXIS Inc.July 2025 Recap & Expert Curated Trade Ideas - newser.com
What institutional flow reveals about SCYNEXIS Inc.Long Setup & Reliable Intraday Trade Alerts - newser.com
Evaluating SCYNEXIS Inc. with trendline analysisJuly 2025 PostEarnings & Weekly High Return Opportunities - newser.com
Metagenomi (NASDAQ:MGX) versus SCYNEXIS (NASDAQ:SCYX) Head-To-Head Analysis - Defense World
Will SCYNEXIS Inc. stock go up soonJuly 2025 Big Picture & Low Risk High Win Rate Stock Picks - newser.com
Is SCYNEXIS Inc. reversing from oversold territoryJuly 2025 Retail & Fast Entry High Yield Tips - newser.com
SCYNEXIS announces favourable Phase I data for SCY-247 trial - Yahoo Finance
SCYNEXIS reports positive Phase 1 results for antifungal drug SCY-247 - Investing.com Nigeria
Scynexis Inc Stock (SCYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):